Outcomes · patients with the initial treatment of venous thromboembolism in patients with cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with the initial treatment of venous thromboembolism in patients with cancer
Dalteparin showed no clear difference in mortality compared with tinzaparin (low certainty).
1 finding from 1 review
Recurrent VTE · patients with the initial treatment of venous thromboembolism in patients with cancer
Dalteparin showed no clear difference in recurrent VTE compared with tinzaparin (low certainty).
1 finding from 1 review
Major bleeding · patients with the initial treatment of venous thromboembolism in patients with cancer
Dalteparin showed no clear difference in major bleeding compared with tinzaparin (low certainty).
1 finding from 1 review
Minor bleeding · patients with the initial treatment of venous thromboembolism in patients with cancer
Dalteparin showed no clear difference in minor bleeding compared with tinzaparin (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · patients with the initial treatment of venous thromboembolism in patients with cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postphlebitic syndrome ‐ not reported · patients with the initial treatment of venous thromboembolism in patients with cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with the initial treatment of venous thromboembolism in patients with cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain intensityVAS 0‐10. Scale from: 0 to 10. · sickle cell disease
1 finding from 1 review
Pain duration ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
The requirement for opiate treatment · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of serious complications of SCD ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of other sickle‐related events ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation (number and duration) ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured · sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found